Pfizer, Baxter, and BCBS talk Real-World Evidence. Will you be there to hear? Join our futuristic and extraordinary free (yes, FREE) 1st Virtual HEOR Conference: “Real World Evidence Virtual Summit: Practical Strategies for Addressing the Needs of Multiple Stakeholders“, December 11, 2014, 8am-5pm ET. Register today!
HEOR & Market Access Writing Workshop, March 26-27, 2015, Philadelphia. Learn more.
|IN THIS ISSUE|
|SPOTLIGHT 1 OF THE WEEK||SPOTLIGHT 2 OF THE WEEK|
|5 Ways to Not Suck At Power Point!|
How many of you have had to sit through a painfully boring PowerPoint presentation that, well, let’s be truthful, sucked? How many of you have actually designed a presentation that sucked? Well, this presentation aims to rid the world of PowerPoint that sucks, by giving you 5 shocking design mistakes you need to avoid. (Source: slideshare).
Wish you knew how your competitors did real-world evidence? Wish you knew what success parameters they considered? Help devise a Checklist for Success for Late-Phase Research by completing this very short survey to gather YOUR insights on what should be on a Checklist for Success for Phase 3, 4, and Observational Studies. Results will be disseminated in an October 20th Webinar and later in a December 11, 2014 virtual meeting on Real World Evidence: Stakeholder Perspectives in HE-Xpo. Take the short Survey and make your views known. (Source: Strategic Market Insight, LLC).
According to a recent survey in the British Medical Journal, about half of its readers believe evidence-based medicine is a malfunctioning. The controversy is not with the system itself, but with kind of evidence that is used. Will evidence-based medicine be able to move beyond its current limits to a more holistic approach? (Source: Project Syndicate, 10/8/14).
When using a country’s wealth as the deciding factor, it’s no wonder patients in the U.S. are suffering, when the country’s wealth belongs to only the top 1 percent! (Source: The Medical Quack, 10/7/14).
This November, as consumers set out to enroll in health insurance plans in the United States, many will find yet another challenge as insures add another generic drug tier to their prescription drug plan. Not only will this mean higher out-of-pocket expenses for consumers, but critics argue that even small price changes effect medical behavior, and will result in a lower quality of care. Read more and let us know what you think about this new scheme. (Source: Trudy Lieberman, medpageTODAY’S KevinMD.com, 10/9/14).
Take a look at the recent approval of new hepatitis C treatments in Specialty Pharmacy Times’, “Keeping an Eye on Hepatitis C Virus Drug Approvals”. (Source: Specialty Pharmacy Times, 8/20/14).
The congress will address New Challenges For Improving European Health Care, including: Creating Sustainable Health Systems in Europe, Earlier Access to Innovation-Is It Worth It?, and Health Care Evidence: Can We Get to the Real World? (Source: ISPOR, 10/7/14).
This handbook provides an overview of the sources of data for conducting ‘real-world’ outcomes research using electronic health records, medical charts, claims and medication databases, alternative population-based data sources, and patient-reported outcomes, as well as other self-reported data. (Source: ISPOR, May 2013).
France has announced plans to selectively tax drug makers when the total cost of their medicines exceeds a certain amount for the year. With an estimated 200,000 people infected with hepatitis C in France, treatment could cost as much as 1 billion Euros ($1.2 Billion). (Source: Ed Silverman, The Wall Street Journal, 9/30/14).
|Link of the Week||Conference of the Week||Webinar of the Week|
|Driving Value through Integrated Payer Market Research|
In this webinar, a mixed methodological case study approach demonstrates how primary and secondary market research with payer audiences can be a key component to inform and successfully drive product launch strategies.